Loading...
01/10 05:58
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals mixed signals: while financial metrics and guidance are stable, regional performance shows declines, and management's clarity on future strategies, particularly regarding Pro2col, is lacking. The Q&A highlights uncertainties about monetization and global rollout, which might concern investors. The market's response is likely neutral due to these offsetting factors.
Net Sales $1.3 billion, down 1.7% versus Q2 of 2024. On a constant currency basis, net sales were flat year-over-year. The decline was attributed to FX headwinds and a 3.1% decrease in volume, which was nearly offset by favorable pricing.
Adjusted EBITDA $174 million, exceeding guidance. Adjusted EBITDA margin was 13.8%, down 30 basis points from last year, driven entirely by unfavorable currency impacts.
Operating Cash Flows $96 million for the quarter, reflecting strong operational efficiencies.
Debt Repayment $55 million in debt repaid during the quarter, maintaining a total leverage ratio of 3x as of June 30.
Gross Profit Margin Improved by 10 basis points to 78%, driven by 70 basis points of favorable pricing and 20 basis points of lower inventory write-downs, partially offset by 60 basis points of foreign currency headwinds and 10 basis points of input cost inflation.
Adjusted Net Income $61 million, with adjusted diluted EPS of $0.59, including an $0.11 FX headwind versus Q2 of 2024.
Adjusted Effective Tax Rate 27.7%, down from 32.3% in Q2 of last year, primarily due to changes in geographic mix of income and discrete events in the period.
Regional Performance - Latin America Reported net sales down 1% year-over-year, but constant currency net sales up 9%, driven by favorable pricing and a 3% increase in volume, offset by FX headwinds.
Regional Performance - North America Net sales down 4%, primarily due to a 6% decline in year-over-year volumes, partially offset by favorable pricing. Sequential improvement in trends noted.
Regional Performance - Asia Pacific Reported net sales down 2% and constant currency net sales down 1%, with a 3% decline in volume and unfavorable sales mix.
Regional Performance - EMEA Net sales flat on a reported basis and down 1% on a local currency basis, with a 5% decline in volume offset by favorable pricing and FX tailwinds.
Regional Performance - China Net sales down 2% year-over-year on both a reported and local currency basis, primarily due to a 6% decline in volumes, partially offset by favorable sales mix.
Healthy Lifespan Product: Entered a new category with the launch of the first healthy lifespan product.
MultiBurn: Launched MultiBurn, a nonpharmaceutical weight loss supplement designed to support metabolic health.
Pro2col App: Beta version launched, integrating data, personalization, coaching, and community for personalized health solutions.
New Product Launches: Introduced Instant Coffee in Mexico, Sleep Enhance in India, and Nutri Muffin in Latin America.
North America Growth: Achieved year-over-year volume growth in July for the first time since April 2021.
Latin America Growth: 16% year-over-year distributor growth in Q2.
Global Expansion: Pro2col app to launch in U.S. and Puerto Rico in Q4, with additional markets in 2026.
Debt Reduction: Paid down $55 million in debt in Q2, maintaining a leverage ratio of 3x.
AI Integration: Leveraging AI for marketing, wellness chat assistant, and distributor support.
Operational Efficiencies: Adjusted EBITDA exceeded guidance at $174 million, with strong cash flows of $96 million.
Transformation to Wellness Platform: Evolving into a data-driven wellness platform with personalized solutions.
Link Biosciences Integration: Integrating Link Biosciences for personalized supplement formulations.
Distributor Engagement: Launched initiatives like Herbalife Flex 45 Challenge and Pro2col beta program to enhance distributor participation.
Market Conditions: Net sales were down 1.7% year-over-year, with constant currency net sales flat. Foreign exchange headwinds negatively impacted results by 170 basis points. Regional sales declines were noted in North America, Asia Pacific, and China, with volume declines contributing to these results.
Competitive Pressures: The company faces challenges in maintaining distributor growth, with global new distributor growth flat year-over-year. North America saw a 6% decline in year-over-year volumes, indicating competitive pressures in the region.
Regulatory Hurdles: Regulatory assessments are underway for expanding personalized wellness solutions globally, which could delay or limit market entry in key regions.
Economic Uncertainties: Foreign exchange fluctuations and input cost inflation impacted financial performance. The company also faces potential risks from enacted tariffs, though they are not expected to materially impact 2025 results.
Strategic Execution Risks: The company is undergoing a significant transformation into a data-driven wellness platform, which involves integrating new technologies like Pro2col and Link Biosciences. These initiatives require substantial investment and carry execution risks, including the need for distributor adoption and effective market rollout.
Supply Chain Disruptions: No explicit mention of supply chain disruptions, but the integration of new technologies and products could pose logistical challenges.
Revenue Expectations: The company has raised and narrowed its full-year net sales guidance range to reflect growing confidence in its outlook. For Q3 2025, net sales growth is projected to be between 0.5% and 4.5% year-over-year, both on a reported and constant currency basis. For the full year 2025, net sales are expected to be in the range of down 1% to up 3% year-over-year, or flat to up 4% on a constant currency basis.
Adjusted EBITDA Projections: For Q3 2025, adjusted EBITDA is expected to be in the range of $150 million to $160 million, or $155 million to $165 million on a constant currency basis. For the full year 2025, adjusted EBITDA is projected to be between $640 million and $660 million, or $685 million to $705 million on a constant currency basis.
Capital Expenditures: Full-year 2025 capital expenditures are expected to be in the range of $75 million to $95 million, reflecting reductions in projected technology-related spending. Capitalized SaaS implementation costs are expected to be between $25 million and $30 million.
Market Trends and Growth: The company anticipates sequential quarterly improvement in North American net sales and volume trends for the remainder of 2025, supported by the launch of new products like MultiBurn and the Pro2col beta release. The global wellness market is projected to reach $5.8 trillion by 2028, providing significant growth opportunities.
Product Launches and Strategic Plans: The Pro2col platform is set for a commercial launch in the U.S. and Puerto Rico in Q4 2025, with additional markets to follow in 2026. The company plans to introduce at-home tests for health and wellness in Q4 2025 and personalized supplement formulations in the first half of 2026. The integration of Link Biosciences is expected to drive long-term differentiation and growth.
The selected topic was not discussed during the call.
The company has shown positive financial performance with debt reduction, regional sales growth, and promising product launches. The Q&A session highlighted strong engagement and feedback for new products, with no anticipated increase in SG&A costs. The raised guidance and strategic focus on subscription revenue and new product lines further support a positive outlook. Despite some lack of detail on profitability differences, overall market sentiment appears optimistic, suggesting a positive stock price movement.
The earnings call reveals mixed signals: while financial metrics and guidance are stable, regional performance shows declines, and management's clarity on future strategies, particularly regarding Pro2col, is lacking. The Q&A highlights uncertainties about monetization and global rollout, which might concern investors. The market's response is likely neutral due to these offsetting factors.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
